NCT06162507CompletedPhase 1/2
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 15 Oct 2024
Brief summary (registry, in English)
This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 29 Nov 2023
- Start date
- 22 Dec 2023
- Primary completion date
- 4 Jul 2024
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06162507
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 24
- From 22 Dec 2023 to the primary completion date, 4 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any major surgery planned during the research period.
Other illness
- With intestinal parasitic infection within the first 6 months of screening.
- With any previous malignant tumors prior to screening.
Other
- With any circumstance that is not suitable to participate in this study.
Who the study is looking for
- With atopic dermatis.
- Voluntarily sign the informed consent form.
Age in the registry: 6 years to 11 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Children's Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.